AU2002347428A1 - Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer - Google Patents

Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Info

Publication number
AU2002347428A1
AU2002347428A1 AU2002347428A AU2002347428A AU2002347428A1 AU 2002347428 A1 AU2002347428 A1 AU 2002347428A1 AU 2002347428 A AU2002347428 A AU 2002347428A AU 2002347428 A AU2002347428 A AU 2002347428A AU 2002347428 A1 AU2002347428 A1 AU 2002347428A1
Authority
AU
Australia
Prior art keywords
methods
ovarian cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002347428A
Inventor
Kurt C. Gish
David H. Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29923401P priority Critical
Priority to US60/299,234 priority
Priority to US31528701P priority
Priority to US60/315,287 priority
Priority to US60/317,544 priority
Priority to US31754401P priority
Priority to US35066601P priority
Priority to US60/350,666 priority
Priority to US60/372,246 priority
Priority to US37224602P priority
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Priority to PCT/US2002/019297 priority patent/WO2002102235A2/en
Publication of AU2002347428A1 publication Critical patent/AU2002347428A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis
AU2002347428A 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer Abandoned AU2002347428A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US29923401P true 2001-06-18 2001-06-18
US60/299,234 2001-06-18
US31528701P true 2001-08-27 2001-08-27
US60/315,287 2001-08-27
US31754401P true 2001-09-05 2001-09-05
US60/317,544 2001-09-05
US35066601P true 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US37224602P true 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/019297 WO2002102235A2 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Publications (1)

Publication Number Publication Date
AU2002347428A1 true AU2002347428A1 (en) 2003-01-02

Family

ID=27540849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002347428A Abandoned AU2002347428A1 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Country Status (6)

Country Link
EP (1) EP1517998A2 (en)
JP (1) JP2005508144A (en)
AU (1) AU2002347428A1 (en)
CA (1) CA2451465A1 (en)
MX (1) MXPA03011979A (en)
WO (1) WO2002102235A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737255B1 (en) 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20060189518A1 (en) * 2002-06-26 2006-08-24 Takeda Pharmaceutical Company Limited Preventing/remedies for cancer
DE10230631A1 (en) * 2002-07-02 2004-01-22 Metagen Pharmaceuticals Gmbh Uses of binding to Ngal substances for diagnosis and treatment of cancer
CA2509684A1 (en) * 2002-07-03 2004-01-15 Sanofi Pasteur Limited Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
CA2510315C (en) 2002-12-20 2014-01-28 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
JP5020636B2 (en) 2003-11-06 2012-09-05 シアトル ジェネティックス, インコーポレイテッド Monomethylvaline compounds that can be conjugated to a ligand
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
WO2005118840A2 (en) * 2004-06-03 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
SG170080A1 (en) 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
CN101421622A (en) 2006-02-17 2009-04-29 儿童医学中心公司 Free NGAL as a biomarker for cancer
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
DK2032701T3 (en) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynucleotides and polypeptides involved in cancer
TWI610939B (en) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 Peptide vaccines for cancers expressing tumor-associated antigens
US9134314B2 (en) 2007-09-06 2015-09-15 Case Western Reserve University Methods for diagnosing and treating cancers
EP2200700B1 (en) 2007-09-26 2016-01-13 Genentech, Inc. Novel antibodies
RS53760B1 (en) 2007-10-01 2015-06-30 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
UA102274C2 (en) 2008-10-22 2013-06-25 Онкотерапі Саєнс, Інк. Epitope peptid rab6kifl/kif20a and vaccines containing it
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
RU2011142974A (en) 2009-03-25 2013-04-27 Дженентек, Инк. NEW ANTIBODIES AGAINST α5β1 AND THEIR APPLICATION
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
CN102933236B (en) 2010-04-15 2014-10-08 斯皮罗根有限公司 Benzene pyrrolo benzodiazepines and combinations thereof
CN103068406B (en) 2010-06-08 2017-06-30 基因泰克公司 Cysteine ​​engineered antibodies and conjugates
EP2621526B1 (en) 2010-09-29 2018-06-06 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
PE09172017A1 (en) 2010-12-20 2017-07-12 Genentech Inc anti-mesothelin antibodies and immunoconjugates
ES2615387T3 (en) 2011-03-31 2017-06-06 Alethia Biotherapeutics Inc. Antibodies against kidney-associated antigen 1 and antigen-binding fragments of these
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
KR101995619B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (en) 2012-10-12 2017-11-28 Adc Therapeutics Sarl pyrrolbenzodiazepine-anti-cd22 antibody conjugates
EP2766048B1 (en) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
RS57104B1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2935273A1 (en) 2012-12-21 2015-10-28 MedImmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
JP6307519B2 (en) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited Pyrrolobenzodiazepine and its conjugates
EP2951592A4 (en) * 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2904044A1 (en) 2013-03-13 2014-09-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TWI636792B (en) 2013-08-12 2018-10-01 建南德克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3055331A1 (en) 2013-10-11 2016-08-17 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
CN107106700A (en) 2013-12-16 2017-08-29 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
KR20160094981A (en) 2013-12-16 2016-08-10 제넨테크, 인크. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531625A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
CN107108724A (en) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 Cysteine engineered antibodies and conjugates
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CA2996902A1 (en) 2015-10-02 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
US10370399B2 (en) 2015-10-20 2019-08-06 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド PROTAC antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648A (en) 2016-06-06 2019-03-15 豪夫迈·罗氏有限公司 Si Weisi groups of antibody-drug conjugates and application method
CN109689111A (en) 2016-08-11 2019-04-26 基因泰克公司 Pyrrolobenzodiazepines * prodrug and its antibody conjugates
CN110139674A (en) 2016-10-05 2019-08-16 豪夫迈·罗氏有限公司 The method for preparing antibody drug conjugate
TW201920192A (en) 2017-09-20 2019-06-01 韓商Ph製藥公司 THAILANSTATIN analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays

Also Published As

Publication number Publication date
EP1517998A2 (en) 2005-03-30
MXPA03011979A (en) 2005-04-08
WO2002102235A2 (en) 2002-12-27
WO2002102235A3 (en) 2005-02-03
CA2451465A1 (en) 2002-12-27
JP2005508144A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
EP1696920B8 (en) Compounds and methods for development of ret modulators
AU2002359414A1 (en) Interposer
AU2002349800A1 (en) Spectroscopic fluid analyzer
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2002309173A1 (en) 5-HT receptor ligands and uses thereof
AU2002214169A1 (en) Phototherapeutical apparatus
AU2002256642A1 (en) Process for the preparation of middle distillates
AU2002235309A1 (en) Anastomosis instrument and method for performing same
AU2002322803A1 (en) Surfaces reconstruction from data point sets
AU2002357119A1 (en) Mitocidal compositions and methods
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003225761A1 (en) Mixing assembly for mixing bone cement
AU2002347305A1 (en) Intumescent gap seals
PL366575A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002241823A1 (en) Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
AU2002323475A1 (en) 2-aroylimidazole compounds for treating cancer
AU6529601A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003270015A1 (en) Compounds, compositions, and methods
AU2001249937A1 (en) Vessel sealing instrument
AU2002237838A1 (en) Isolated ductal fluid sample
AU2002360766A1 (en) Methods for cancer imaging
AU2002324717A1 (en) Test enabled application execution
AU2002359200A1 (en) New composition
AU2002320762A1 (en) Immunostimulatory oligodeoxynucleic molecules

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase